Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies

Drug Metabolism Reviews

Volumn 35, Issue 4, 2003, Pages 393-415

  Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Clearance; CYP inhibition potential; Drug drug interactions; In vitro technologies; In vitro in vivo correlations; Prediction of human pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; ERYTHROMYCIN; FELODIPINE; HALOPERIDOL; MIDAZOLAM; NIFEDIPINE; PROGESTERONE; QUINIDINE; SIMVASTATIN; TERFENADINE; TESTOSTERONE; WARFARIN;

AREA UNDER THE CURVE; BINDING SITE; CONFERENCE PAPER; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; IN VITRO STUDY; MATHEMATICAL ANALYSIS; MICHAELIS CONSTANT; MODEL; PARAMETER; PHARMACOKINETICS; VALIDATION PROCESS;

HUMANS; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0346992330     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120026870     Document Type: Conference Paper

References (48)

1. Atkins, W. M., Lu, W. D., Cook, D. L. (2002). Is there a toxicological advantage for nonhyperbolic kinetics in cytochrome P450 catalysis? J. Biol. Chem. 277:33258-33266.
2. Davis, J. D., Aarons, L., Houston, J. B. (1994). Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. Pharm. Res. 11:1424-1428.
3. Davit, B., Reynolds, K., Yuan, R., Ajayi, F., Conner, D., Fadiran, E., Gillespie, B., Sahajwalla, C., Huang, S. M., Lesko, L. J. (1999). FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J. Clin. Pharmacol. 39:899-910.
4. Domanski, T. L., HE, Y.-A., Khan, K. K., Roussel, F., Wang, Q., Halpert, J. R. (2001). Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150-10160.
5. Egnell, A.-C., Houston, J. B., Boyer, S. (2003). In vivo heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine cooperativity. J. Pharmacol. Exp. Ther. 305:1251-1262.
6. Ervine, C. M., Matthew, D. E., Brennan, B., Jezequel, S. G., Humphrey, M. J., Houston, J. B. (1996). Comparison of the steady-state pharmacokinetics of fluconazole and ketoconazole and their relative effects on cytochrome P450 activity in rats: use of antipyrine and a steady-state infusion approach to assess plasma concentration-response relationships. Drug Metab. Dispos. 24:211-215.
7. Galetin, A., Clarke, S. E., Houston, J. B. (2002). Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 30:1512-1522.
8. Galetin, A., Clarke, S. E., Houston, J. B. (2003). Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab. Dispos. 31:1108-1116.
9. He, Y. A., Roussel, F., Halpert, J. R. (2003). Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch. Biochem. Biophys. 409:92-101.
10. Hosea, N. A., Miller, G. P., Guengerich, F. P. (2000). Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
11. Houston, J. B. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-1479.
12. Houston, J. B., Carlile, D. J. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab. Rev. 29:891-922.
13. Houston, J. B., Kenworthy, K. E. (2000). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28:246-254.
14. Houston, J. B., Kenworthy, K. E., Galetin, A. (2003). Typical and atypical enzyme kinetics. In: Fisher, M., Lee, J., Obach, S., eds. Drug Metabolizing Enzymes: Cytochome P450 and Other Enzymes in Drug Discovery and Development. Lausanne: FontisMedia, pp. 211-254.
15. Hutzler, J. M., Frye, R. F., Korzekwa, K. R., Branch, R. A., Huang, S.-M., Tracy, T. S. (2001a). Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur. J. Pharm. Sci. 14:47-52.
16. Hutzler, J. M., Hauer, M. J., Tracy, T. S. (2001b). Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 29:1029-1034.
17. Ito, K., Houston, J. B. (In press). Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
18. Ito, K., Houston, J. B. (In press). Prediction of human drug clearance from in vitro and preclinical data using physiologically-based and empirical approaches.
19. Ito, K., Brown, H. S., Houston, J. B. (In press). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.
20. Ito K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., Sugiyama, Y. (1998). Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50:387-411.
21. Ito, K., Chiba, K., Horikawa, M., Ishugami, M., Mizuno, N., Aoki, J., Gotoh, Y., Iwatsubo, T., Kanamitsu, S., Kato, M., Kawahara, I., Niinuma, K., Nishino, A., Sato, N., Tsukamoto, Y., Ueda, K., Itoh, T., Sugiyama, Y. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS Pharm. Sci. 4(article 25).
22. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., Sugiyama, Y. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73:147-171.
23. Kanamitsu, S., Ito, K., Sugiyama, Y. (2000). Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 17:336-343.
24. Kenworthy, K. E., Clarke, S. E., Andrews, J., Houston, J. B. (2001). Multi-site kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29:1-8.
25. Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J., Tracy, T. S. (1998). Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
26. Lin, J. H. (2000). Sense and nonsense in the prediction of drug-drug inter-actions. Curr. Drug Metab. 1:305-331.
27. Lin, J. H., Lu, A. Y. H. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49:403-449.
28. Lu, P., Lin, Y., Rodrigues, A. D., Rushmore, T. H., Baillie, T. A., Shou, M. (2001). Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethylcoumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab. Dispos. 29:1473-1479.
29. Mahmood, I., Balian, J. D. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 9:887-895.
30. Naritomi, Y., Terashita, S., Kimura, S., Suzuki, A., Kagayama, A., Sugiyama, Y. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29:1316-1324.
31. Ngui, J. S., Tang, W., Stearns, R. A., Shou, M., Miller, R. R., Zhang, Y., Lin, J. H., Baillie, T. A. (2000). Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab. Dispos. 28:1043-1050.
32. Ngui, J. S., Chen, Q., Shou, M., Wang, R. W., Stearns, R. A., Baillie, T. A., Tang, W. (2001). In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug. Met. Dispos. 29:877-886.
33. Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., MacIntyre, F., Rance, D. J., Wastall, P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 283:46-58.
34. Rodrigues, A. D., Winchell, G. A., Dobrinska, M. R. (2001). Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J. Clin. Pharmacol. 41:368-373.
35. Segel, I. H. (1975). Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State enzyme Systems. New York: Wiley & Sons Inc.
36. Shou, M., Dai, R., Cui, D., Korzekwa, K. R., Baillie, T. A., Rushmore, T. H. (2001b). A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 276:2256-2262.
37. Shou, M., Lin, Y., Lu, P., Tang, C., Mei, Q., Cui, D., Tang, W., Ngui, J. S., Lin, C. C., Singh, R., Wong, B. K., Yergey, J. A., Lin, J. H., Pearson, P. G., Baillie, T. A., Rodrigues, A. D., Rushmore, T. H. (2001a). Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2:17-36.
38. Stone, A. N., Mackenzie, P. I., Galetin, A., Houston, J. B., Miners, J. O. (2003). Isoform-selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos. 31:1086-1089.
39. Tang, W., Stearns, R. A. (2001). Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2:185-198.
40. Tang, W., Stearns, R. A., Kwei, G. Y., Iliff, S. A., Miller, R. R., Egan, M. A., Yu, N. X., Dean, D. C., Kumar, S., Shou, M., Lin, J. H., Baillie, T. A. (1999). Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J. Pharmacol. Exp. Ther. 291:1068-1074.
41. Tucker, G. T., Houston, J. B., Huang, S.-M. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin. Pharmacol. Ther. 70:103-114.
42. von Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Duan, S. X., Harmatz, J. S., Shader, R. I. (1994). Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268:1278-1283.
43. Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., Lu, A. Y. H. (2000). Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28:360-366.
44. Williams, J. A., Ring, B. J., Cantrell, V. E., Campanelle, K., Jones, D. R., Hall, S. D., Wrighton, S. A. (2001). Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab. Dispos. 30:1266-1273.
45. Witherow, L. Y., Houston, J. B. (1999). Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J. Pharmacol. Exp. Ther. 290:58-65.
46. Yao, C., Levy, R. H. (2002). Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J. Pharm. Sci. 91:1923-1935.
47. Zomorodi, K., Houston, J. B. (1995). Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharm. Res. 12:1642-1646.
48. Zuegge, J., Schneider, G., Coassolo, P., Lave, T. (2001). Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin. Pharmacokin. 40:553-563.